4 results about "Angiogenesis Effect" patented technology

The application is a kind of nanoscale enzyme multifunctional composite hydrogel and its preparation method and application, belonging to the field of biological medicine technology. In view of the problem that the existing materials or drugs have poor treatment effect on infected wound, the application comprises the following steps: preparing solution A and solution B respectively, standby, preparing Cu-TCPP-Mn nanosheet, obtaining Cu-TCPP-Mn nanodot after further treatment, adding the activated Cu-TCPP-Mn nanodot into solution A to obtain mixed solution C with a concentration of 5 mu g / mL, adding the activated PRP solution into solution B to obtain mixed solution D with a concentration of 100 mu g / mL, and mixing the mixed solution C and the mixed solution D in equal volume to obtain CHPM composite hydrogel. The CHPM composite hydrogel can effectively reduce the oxidative stress level of acute infected wound tissue, provide a suitable oxidative microenvironment for PRP to play a role in promoting angiogenesis, and accelerate the healing of acute infected wound.

The present disclosure provides human placenta-derived proangiogenic stem cells hPASCs and applications thereof. The human placenta-derived proangiogenic stem cells hPASCs of the present disclosure are preserved in the China Center for Type Culture Collection, Wuhan University, Wuhan, China, on April 2, 2025, with the preservation number CCTCC NO: C202592. The hPASCs of the present disclosure contain a subpopulation of angiogenic cells and have stem cell "stemness", and have angiogenic effects in vitro and in vivo, and can be used for the treatment of cardiovascular diseases and other diseases, and the vascularization of artificial organs and tissues.

The invention relates to compositions comprising a microRNA having a pro-angiogenic effect. In particular, the invention relates to a composition comprising a microRNA selected from hsa-miR-4691-5p, hsa-miR-4496, hsa-miR-582-5p, and hsa-miR-345-3p. The invention further relates to nucleic acid molecules encoding at least one of these microRNAs and viral particles capable of expressing these microRNAs in a cell. The invention further relates to the use of these microRNAs, nucleic acid molecules or viral particles as medicine, particularly in the treatment of a cardiovascular disease.